# Table of Contents

Welcome from the Chair of the 2016 POGO Multi-Disciplinary Symposium on Childhood Cancer Planning Committee 4

2016 POGO Multi-Disciplinary Symposium on Childhood Cancer Planning Committee 5

Synopsis, Learning Objectives 6

Conflict of Interest Declaration, Accreditation Details, Posters, Audience-Response System 7

Program at a Glance 8-9

Faculty 10-16

**ABSTRACTS**

A Multidisciplinary Approach to Educating the Patient and Family with a New Acute Lymphoblastic Leukemia Diagnosis 17

A New Mouse Model of Pre-B Cell Acute Lymphoblastic Leukemia Induced by Deletion of the Genes Encoding PU.1 and SPI-B 18

Adolescent and Young Adult (AYA) Oncology Program at the Hospital for Sick Children 19

Adrenal Insufficiency in Pediatric Patients During Maintenance Treatment for Acute Lymphoblastic Leukemia 20

Brain structure, working memory and response inhibition in childhood leukemia survivors 21

Cancer Genetics Referral Criteria: The McGill Interactive Pediatric Oncogenetic Guidelines (MIPOGG) and its Pilot Study: Pediatric Renal Tumors: A Retrospective Study Validating Cancer Genetics Referral Criteria based on MIPOGG 22

Central Adiposity in Children with Brain Tumors: A Report from the Canadian Study of Determinants of Endometabolic Health (CanDECIDE) Study 23

Development of a Comprehensive Leukemia Clinic at Children’s Hospital of Wisconsin 24

Embryonal Tumors in Canadian Children: Results from the Canadian Pediatric Brain Tumor Consortium 25

Evaluation of a Joint Adult/Pediatric AfterCare Clinic for Cancer Survivorship Care 26

Feasibility and Safety of Full Dose Anticoagulation Therapy in the Context of Thrombocytopenia in Children Treated for Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma 27

Folate, vitamin B12 and iron status and cognitive and behavioural late-effects in survivors of childhood acute lymphoblastic leukemia 28

Genetic Predictors of Intellectual Outcome in Children treated for Medulloblastoma 29

Genetic Testing in Dicer1 Syndrome and Proposal of a Surveillance Protocol 30

Health-related quality of life in molecular subgroups of Medulloblastoma 31

Hippocampal Subfield Volumes and Associative Memory in Pediatric Brain Tumor Survivors 32

Identifying Drug-Resistant Mutations in EBF1-PDGFRB Ph-Like Acute Lymphoblastic Leukemia 33

Impaired neural function during visual-motor performance in children treated for brain tumors 35

Implementation of an Electronic Tracking Board System in an Ambulatory Pediatric Oncology Clinic 36

Incidence Trends and Projections for Childhood Cancer in Ontario 1986-2025 37
Dear Symposium delegates,

Welcome to the 2016 POGO Symposium! I am thrilled to see a diverse and multi-disciplinary audience represented here today from across Canada, the United States and as far away as Nigeria.

The planning committee is comprised of professionals from both tertiary and satellite clinics across Ontario, with representation from medicine, nursing, social work, psychology and pharmacy. We are particularly proud of this year’s program, focused on the theme – Leukemia: Successes, Advances, Challenges.

Leukemia boasts the dubious distinction of being the most common form of childhood cancer. It is a disease that has seen both unparalleled improvements in treatment and survival rates, yet continues to pose great challenges. The planning committee set out to design a program that would cover a range of topics related to this group of diseases.

The symposium is bookmarked by plenary talks from two pioneers in the field. This morning, you will hear from Dr. Stephen Sallan about the evolution of care and research in childhood leukemia over the last five decades, a story that’s as inspiring as it is fascinating. And tomorrow afternoon, Dr. Ching Hon-Pui, will discuss what future management of children with acute lymphoblastic leukemia might look like, leaving us all to dream about what might be possible for our current and future patients. Over the course of the next two days, this program will cover everything from innovative therapies (including Molecular Precision Medicine and CAR-T Cell Therapy) to behavioural and neurocognitive and other late effects of treatment; to the unique challenges of the Rare Leukemias (including JMML, CML and Ph+ ALL). Changes that health professionals face when caring for patients with ALL, including medication compliance, the punishing duration of treatment, and the rare and exceedingly challenging cases involving infants diagnosed with ALL will be addressed. The different but equally perplexing issues arising with AML, including management of the patient with Down Syndrome, the high infection-related mortality rate, and the search for better therapies will be similarly explored. And those topics common to all forms of leukemia, such as chronic complications of treatment and the need for effective, consistent supportive care will be discussed. We hope this program will illuminate the issues that continue to challenge each of our respective disciplines and offer solutions that we might continue to improve our care for these patients.

I would be remiss if I did not mention and thank our many sponsors and exhibitors for supporting this initiative; please be sure to visit their booths and say hello! In addition, there are 40 posters in the ballroom foyer and surrounding area, representing what’s new in pediatric oncology research. Please be sure to visit all of the poster presenters and submit your completed passport for a chance to win a free registration for next year’s Symposium.

It is the planning committee’s hope that the next two days will provide the opportunity for new and renewed conversations, for the exchange of ideas and for continued learning.

Thank you all for attending… I hope you enjoy the 2016 POGO Symposium!

Sincerely,

David Malkin, MD, FRCPC
Medical Director and POGO Chair in Childhood Cancer Control, 2011-2016
Chair, 2016 POGO Symposium Planning Committee
Professor of Pediatrics and Medical Biophysics, University of Toronto
Staff Oncologist, Division of Hematology/Oncology
Senior Scientist, Genetics & Genomic Biology Program, Research Institute
The Hospital for Sick Children
Planning Committee

POGO gratefully acknowledges the members of the 2016 Symposium planning committee:

SARAH ALEXANDER, MD, FRCP(C)
Clinical Director
Pediatric Oncologist
The Hospital for Sick Children, Toronto, ON

MYLÈNE BASSAL, MD, FRCP(C)
Pediatric Hematologist-Oncologist
Program Leader, Oncology AfterCare Program
Children’s Hospital of Eastern Ontario, Ottawa, ON

DANIELLE CATAUDELLA, Psy.D., CPsych
Psychologist
Children’s Hospital, London Health Sciences Centre, London, ON

BRUNA DIMONTE, RN, BScN
Senior Database Administrator and Co-Privacy Officer
Pediatric Oncology Group of Ontario (POGO)

LISA EGAN-BATES, RN, BScN
POGO Pediatric Oncology Satellite Nurse Coordinator
Southlake Regional Health Centre, Newmarket, ON

JANET GAMMON, RN, BScN
Clinical Program Coordinator, Neuro-oncology
The Hospital for Sick Children, Toronto, ON

PAUL GIBSON, MD, FRCP(C)
Pediatric Oncologist
Children’s Hospital, London Health Sciences Centre, London, ON
Medical Officer
Pediatric Oncology Group of Ontario (POGO)

CORIN GREENBERG, PhD
Chief Executive Officer
Pediatric Oncology Group of Ontario (POGO)

ALAN HUDAK, MD, FRCP(C), FAAP
Pediatrician, Medical Director, POGO Satellite Program
Orillia Soldiers’ Memorial Hospital, Orillia, ON

DONNA JOHNSTON, MD, FRCP(C), FAAP
Chief, Division of Pediatric Hematology/Oncology
Children’s Hospital of Eastern Ontario, Ottawa, ON
Professor, Department of Pediatrics, University of Ottawa

HEATHER JONES, MN, NP - Paediatrics
Nurse Practitioner – Pediatrics
Leukemia/Lymphoma Section, Div. of Haematology/Oncology
The Hospital for Sick Children, Toronto, ON

DAVID MALKIN, MD, FRCP(C) (Chair)
Medical Director and POGO Chair in Childhood Cancer Control, 2011-2016
Pediatric Oncology Group of Ontario (POGO)
Professor of Pediatrics and Medical Biophysics,
University of Toronto
Staff Oncologist, Division of Hematology/Oncology
Senior Scientist, Genetics & Genomic Biology Program, Research Institute
The Hospital for Sick Children, Toronto, ON

DIANA MASSE, RN, BScN
Nurse Case Manager
Children’s Hospital, London Health Sciences Centre, London, ON

CORY MURPHY, RN, BScN
POGO Interlink Nurse
The Hospital for Sick Children, Toronto, ON

PAUL NATHAN, MD, M.Sc., FRCP(C)
Director, AfterCare Program, Division of Haematology/Oncology
The Hospital for Sick Children, Toronto, ON

CAROL PORTWINE, MD, FRCP(C), PhD
Pediatric Hematologist/Oncologist
McMaster Children’s Hospital, Hamilton, ON
Associate Professor, Department of Pediatrics
McMaster University, Hamilton, ON

GUYLAINE ROBICHAUD, BSW, RSW
Social Worker
Children’s Hospital of Eastern Ontario, Ottawa, ON

JOHN T. WIERNIKOWSKI, BScPhm, PharmD
Clinical Pharmacist
McMaster Children’s Hospital, Hamilton, ON
Clinical Assistant Professor, Department of Pediatrics
McMaster University, Hamilton, ON
Synopsis

The 2016 POGO Multi-Disciplinary Symposium on Childhood Cancer – Leukemia: Successes, Advances, Challenges – will examine clinical and scientific advances in the diagnosis and treatment of leukemia in children and adolescents and highlight the impact of this disease on patients, parents and survivors. Pediatric oncologists, nurses, social workers, and other health professionals will enhance their knowledge of diagnostic and treatment innovations for various forms of leukemia, and improve their ability to manage the physical and psychosocial effects that are common to patients with this disease.

Learning Objectives

Participants will be able to:

1. Discuss the role of molecular precision medicine in treating Acute Lymphoblastic Leukemia (ALL).
2. Recognize and mitigate behavioural challenges common in children with ALL, including anxiety and depression.
3. Explain the implications of treatment for ALL on attention, memory, and learning and discuss possible interventions.
4. Summarize treatment options for childhood Acute Myeloid Leukemia (AML) and the challenges in evaluating targeted therapies.
5. Summarize the biology and treatment approaches for various rare leukemias, including: Juvenile myelomonocytic leukemia (JMML), Chronic myeloid leukemia (CML) and Ph-positive ALL.
6. Explain why leukemia occurs more frequently in patients with Down syndrome and describe treatment approaches for this population.
7. List practical strategies to address compliance issues in children and adolescents undergoing treatment for ALL.
8. Summarize the biology and diverse therapeutic approaches to the treatment of infant ALL.
9. Discuss the prevalence of allergies to Asparaginase and explain how to adapt dosage in these cases.
10. Summarize various supportive care options for pediatric leukemia patients.
11. Describe CAR-T Cell therapy as a treatment for ALL.
12. Recognize the signs of and mitigate deteriorating bone health in pediatric ALL patients.
13. Summarize common complications related to the treatment of leukemia, including pain, fatigue and obesity, and discuss possible interventions.
14. Describe the risk for serious morbidity and premature mortality (late effects) in survivors of childhood leukemia.
15. Explain in one's own words the ways in which treatment for leukemia is likely to evolve and change in the next 10-20 years.
Declaration of Potential Conflict of Interest

Speakers have been asked to disclose to the audience any real or apparent conflict(s) of interest that may have direct bearing on the subject matter of this program.

Accreditation

Royal College of Physicians and Surgeons of Canada – Section 1

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, approved by Continuing Professional Development, Faculty of Medicine, University of Toronto up to a maximum of 12.5 hours.

The American Medical Association - AMA PRA Category 1

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at: www.ama-assn.org/go/internationalcme

Oncology Nursing Society (ONS) – Nursing Accreditation

This continuing nursing education activity has been approved for 11.5 contact hours by the Oncology Nursing Society, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

Posters

The 2016 Symposium features nearly 40 posters related to the care and control of malignant disease in children. Submissions cover all aspects of childhood cancer care and control. Be sure to visit each poster presenter in the Prince and Duncan foyers to get your poster passport stamped. Hand in your completed passport (including your vote for best overall poster) at the registration desk for a chance to win a free registration to next year’s Symposium!

Audience Response System

New this year, POGO has partnered with Data on the Spot (D.O.T.S.) to provide an audience response system (i.e., ‘clickers’) for everyone in the audience. Your clicker is included in your delegate bag and instructions for use will be communicated at the start of the conference. If you have any questions about how to use it, please visit the registration desk.
Program, Day 1 - Friday, November 4

7:30 am – 8:25 am • Registration & Continental Breakfast

8:25 am – 8:30 am • Opening Remarks
David Malkin, MD, FRCPC

8:30 am – 9:15 am
The Long and Winding Road – A Brief History of Pediatric Leukemia
Stephen Sallan, MD

9:15 am – 10:00 am
Molecular-Precision Medicine and the Story with Acute Lymphoblastic Leukemia (ALL)
Mignon Loh, MD

10:00 am – 10:15 am • Morning Break (Poster Boards on display)

10:15 am – 11:00 am
Managing Behavioural Changes During and After Treatment for Leukemia
Nina Kadan-Lottick, MD, MSPH

11:00 am – 11:45 am
Quick Hits (15 mins each):
1. Immunizations – Marina Salvadori, MD, FRCPC
2. KiCS and PROFYLE: Precision Medicine Initiatives – David Malkin, MD, FRCPC

11:45 am – 12:15 pm
Implications of Treatment for ALL on Attention, Memory, and Learning
Sharon Guger, PhD

12:15 pm – 1:15 pm • Lunch (Poster Boards on Display)

1:15 pm – 2:00 pm
Management of Bone Health in Children and Adolescents with ALL
Leanne Ward, MD, FRCPC, FAAP

2:05 pm – 3:05 pm
Workshop A – Biology, Diagnosis and Treatment of Rare Leukemias
Crown Room
Jeff Lipton, PhD, MD, FRCPC; Mignon Loh, MD; Jim Whitlock, MD

Workshop B – Leukemia in the Down Syndrome Population
Prince Ballroom
Kim S. Daniel, M.Ed, PhD; Johann Hitzler, MD; Jeffrey W. Taub, MD

Workshop C – Staying the Course: Addressing Compliance Challenges in the Treatment of Pediatric Leukemia
Princess Room
Wendy Landier, PhD, CRNP; Mark D. Minden, PhD, MD, FRCPC

Workshop D – Tiny Patients, Enormous Challenges: Treatment Approaches for Infant ALL
North York Room
Patrick Brown, MD; Jennifer Drynan-Arsenault, BSc, BScPhm, RPh, ACPR; Krista Johnston, BScPT, MScPT(c)

3:05 pm – 3:45 pm • Dedicated Poster Viewing time (Refreshments Available)

3:45 pm – 4:15 pm
Asparaginase: The Good, the Bad and the Ugly
Paul Gibson, MD, FRCPC; Lee Dupuis, RPh, PhD; Stephen Sallan, MD

4:15 pm – 5:00 pm
Toxicity Management: Supportive Care Options for Children with Leukemia
Lillian Sung, MD, PhD
Program, Day 2 - Saturday, November 5

8:00 am – 8:55 am • Continental Breakfast

8:55 am – 9:00 am • Opening Remarks
David Malkin, MD, FRCPC

9:00 am – 9:45 am
The CAR-T Cell Revolution in Hematologic Malignancies
Stephan Grupp, MD, PhD

9:45 am – 10:30 am
Future Targets for Acute Myeloid Leukemia (AML)
Edward Anders Kolb, MD

10:30 am – 10:45 am
Poster Presentations:
1. Brain Structure, Working Memory and Response Inhibition in Childhood Leukemia Survivors
   Ellen van der Plas, PhD, Research Fellow, SickKids
2. Adrenal Insufficiency in Pediatric Patients During Maintenance Treatment for ALL
   Mary-Pat Schlosser, MD; Hematology/Oncology Fellow, Children's Hospital of Eastern Ontario, University of Ottawa
3. Therapeutic Implications of Molecular Biomarkers in Infants with Pediatric Low-grade Glioma
   Ana Guerreiro Stucklin, MD, PhD; Clinical and Research Fellow, Division of Haematology/Oncology, The Hospital for Sick Children
4. A Multidisciplinary Approach to Educating the Patient and Family with a new ALL Diagnosis
   Jeneane Sullivan, MSN, RN, CPON; Oncology Patient/Family Education Specialist, Children’s Hospital of Philadelphia
5. Feasibility and Safety of Full Dose Anticoagulation Therapy in the Context of Thrombocytopenia in Children Treated for ALL and Lymphoblastic Lymphoma
   Mihir Bhatt, MD, FRCPC; Pediatric Oncologist, McMaster University

10:45 am – 11:00 am • Morning Break & Poster Viewing

11:00 am – 12:00 pm
Workshop A – Biology, Diagnosis and Treatment of Rare Leukemias
Crown Room
Jeff Lipton, PhD, MD, FRCPC; Mignon Loh, MD; Jim Whitlock, MD

Workshop B – Leukemia in the Down Syndrome Population
North York Room
Kim S. Daniel, M.Ed, PhD; Johann Hitzler, MD; Jeffrey W. Taub, MD

Workshop C – Staying the Course: Addressing Compliance Challenges in the Treatment of Pediatric Leukemia
Princess Room
Wendy Landier, PhD, CRNP; Mark D. Minden, PhD, MD, FRCPC

Workshop D – Tiny Patients, Enormous Challenges: Treatment Approaches for Infant ALL
Prince Ballroom
Patrick Brown, MD; Jennifer Drynan-Arsenault, BSc, BScPhm, RPh, ACPR; Krista Johnston, BScPT, MScPT(c)

12:10 pm – 1:10 pm
Pain, Fatigue and Obesity: Managing Chronic Complications while on Therapy and Beyond
Ellen Lavoie Smith, PhD, APRN, AOCN, FAAN; Steven Mittelman, MD, PhD; Sue Zupanec, MN, NP-Pediatrics

1:10 pm – 1:30 pm • Lunch Buffet Opens for Lunch ’n Learn Sessions

1:30 pm – 2:15 pm
Caring Beyond the Cure: Long-term Outcomes in Survivors of Childhood Leukemia
Paul Nathan, MD, MSc, FRCPC

2:15 pm – 3:00 pm
The Future of Leukemia Therapy
Ching-Hon Pui, MD

3:00 pm – 3:05 pm • Closing Remarks
Faculty

Nicole Bradley, MHSc
Senior Healthcare Analyst & Project Manager
Pediatric Oncology Group of Ontario (POGO)

Nicole Bradley has a Masters of Health Science (MHSc) degree in Community Health & Epidemiology from the University of Toronto. Nicole has been involved in a variety of research studies and applied analyses related to epidemiology, health services research, policy development and quality of life in pediatric and adult oncology - with 18 peer-reviewed publications and over 30 oral and poster presentations based on this work. Nicole has been awarded with numerous recognitions for her work as a young investigator, including recognition for one of the “top ten Canadian Cancer Society funded research studies of 2010.” Since 2009, Nicole has been involved with policy and program development with POGO. She is particularly interested in the use of evidence to support policy and program development and health system design to improve the quality of the healthcare system.

Patrick Brown, MD
Director, Childhood Leukemia Program
Johns Hopkins University, Baltimore, MD
Sidney Kimmel Cancer Center, Baltimore, MD

Dr. Pat Brown received his medical degree from the Medical University of South Carolina, in Charleston. He subsequently completed an internship and residency in pediatrics at Johns Hopkins, and went on to a three-year joint clinical fellowship with Johns Hopkins and the National Cancer Institute in pediatric hematology-oncology.

Dr. Brown is a member of the American Society of Hematology, the American Association for Cancer Research, and the American Society of Pediatric Hematology/Oncology. He is vice-chair for relapse and an executive steering committee member of the Acute Lymphoblastic Leukemia (ALL) Committee in the Children’s Oncology Group, and he co-chairs the National Comprehensive Cancer Network’s Clinical Guidelines Panel for ALL. He has been published in over 50 peer-reviewed journal articles and book chapters.

His research focuses on developing new therapies for childhood leukemia—specifically, leukemias with very low cure rates. His laboratory is working to develop new treatments that can overcome resistance to chemotherapy and that, unlike chemotherapy, selectively target leukemia-causing mutations. He is a principal investigator on several clinical trials testing promising combinations of standard chemotherapy with novel targeted drugs.

Kim Daniel, M.Ed., PhD
Professional Psychologist
Hematology/Oncology Division and Psychology Department
The Hospital for Sick Children, Toronto, ON

Dr. Kim S. Daniel received her PhD from McGill University, in Psychology, and completed her predoctoral internship at Surrey Place Centre (SPC) in Toronto, working with individuals with differing intellectual disabilities. She completed a postdoctoral clinical fellowship at Toronto’s Hospital for Sick Children (SickKids), working within the Paediatric Clinical/Health Psychology and Behavioural Medicine division. Currently, Dr. Daniel is employed in differing settings. At SPC, she provides cognitive assessments and psychological interventions within the Child and Youth division. At SickKids, she provides psychotherapy working within the Haematology/Oncology division. At CBT and Associates of Toronto, she provides cognitive behavioural therapy (CBT) for children, adolescents, adults, and families. At ADLER, she is an adjunct professor and teaches CBT approaches and strategies. Notably, Dr. Daniel’s main aspiration is to give back to her community whereby she is able to apply her 15+ years of clinical experiences and education in supporting individuals with severe emotional, behavioral, social, cognitive and medical challenges that negatively impact their overall health and level of functioning across differing environments. Lastly, Dr. Daniel also likes to contribute to research and currently, as joint authorship, has a book chapter under review titled: “Easing Psychological Distress throughout the Pediatric Cancer Journey.”

Jennifer Drynan-Arsenault, BSc, BScPhm, RPh, ACPR
Clinical Pharmacist, Division of Haematology/Oncology and Bone Marrow Transplantation
The Hospital for Sick Children, Toronto, ON

Jennifer attended Queen’s University where she studied biology prior to completing a pharmacy degree at the University of Toronto. She completed her pharmacy residency at Sunnybrook and Women’s College Hospital. After practicing in adult oncology at Mount Sinai Hospital, she moved to The Hospital for Sick Children where she works in both the inpatient and outpatient setting within the Division of Haematology/Oncology and Bone Marrow Transplantation.

Lee Dupuis, RPh, PhD
Associate Scientist and Clinical Pharmacist
The Hospital for Sick Children, Toronto, ON

Lee has a BSc, BScPhm and MScPhm from the University of Toronto. She completed her pharmacy residency at Sunnybrook Health Sciences Centre and her PhD at the University of Amsterdam. She has held several positions at The Hospital for Sick Children (SickKids) including Coordinator of Drug
Lee’s research focuses on the supportive care of children with cancer or undergoing bone marrow transplant with a focus on improving control of chemotherapy-induced nausea and vomiting and creating ways that children can communicate the severity of treatment-related adverse effects. Lee serves on committees within the Children’s Oncology Group, POGO and C17 and on guideline development panels for POGO, American Society of Clinical Oncology, the Dutch Children’s Oncology Group and the Multinational Association of Supportive Care in Cancer.

Paul Gibson, MD, FRCP$C$
Pediatric Oncologist, Children’s Hospital, London Health Sciences Centre (LHSC), London, ON
Medical Officer, Pediatric Oncology Group of Ontario
Assistant Professor, Western University, London, ON

Dr. Gibson is a Graduate of Queen’s University’s Medical School. He completed Pediatric Residency training at B.C. Children’s Hospital prior to subspecialty training at The Hospital for Sick Children. He joined the Section of Pediatric Hematology and Oncology at Children’s Hospital full time in 2010. He has served as Physician Lead in the LHSC Computerized Provider Order Entry project and is currently a Physician Lead in the PowerChart Oncology project. Dr. Gibson has served as Medical Officer of the Pediatric Oncology Group of Ontario (POGO) since 2015. His role with POGO includes medical support of the POGO Satellite program and a member of the executive oversight committee of the Provincial Pediatric Oncology Planning process.

Stephan Grupp, MD, PhD
Novotny Professor of Pediatrics
University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
Director, Cancer Immunotherapy Frontier Program
Director of Translational Research

Stephan Grupp MD, PhD, is the Director of the Cancer Immunotherapy Frontier Program, as well as Director of Translational Research in the Center for Childhood Cancer Research at the Children’s Hospital of Philadelphia (CHOP), and the Yetta Dietch Novotny Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania. His primary area of clinical research is the use of engineered cell therapies for high-risk pediatric cancers, and he is leading the largest and most successful CAR T cell (engineered T cell therapy) clinical trials conducted to date (referred to as CART19 and/or CTL0191,2). He is a member of the Stem Cell Transplant Section of the Division of Oncology, is Medical Director of the Stem Cell Laboratory and Program Director of the Heme-Onc Fellowship program.

Dr. Grupp graduated from the University of Cincinnati after completing the MD/PhD program with a PhD in Immunology. He completed pediatric residency at the Boston Children’s Hospital, followed by a fellowship in Pediatric Hematology/Oncology at the Dana Farber Cancer Institute and postdoctoral work in Immunology at Harvard University. His primary laboratory interest is the development of new cell therapy treatments for pediatric cancers and the molecular control of leukemic cell growth.

Sharon Guger, PhD
Pediatric Neuropsychologist, AfterCare Program
The Hospital for Sick Children, Toronto, ON

Dr. Sharon Guger received her PhD in clinical-developmental psychology at York University in 2000 and then completed a post-doctoral fellowship in paediatric neuropsychology at The Hospital for Sick Children (SickKids) with Dr. Brenda Spiegler. Her 16 years of experience as a neuropsychologist have included clinical practice, research, and teaching.

Dr. Guger is a pediatric neuropsychologist with the AfterCare Program in the Division of Haematology/Oncology where she provides neuropsychology assessment and consultation services primarily to children, teens and transition-aged young adults with a history of leukemia/lymphoma or brain tumours. As well, she is involved in efforts at promoting transition to adult health-care at both individual and systemic levels. Dr. Guger’s research has focused on developing a better understanding of the long-term outcomes of children and youth with leukemia and brain tumours. Specifically, she is interested in individual and contextual variables that influence disease and treatment-related neurocognitive and psycho-social deficits with the goal of identifying those at greatest risk in order to implement targeted interventions and promote optimal outcome. Dr. Guger is also the Director of Clinical Psychology Training in the Department of Psychology, responsible for practicum, pre-doctoral internship and post-doctoral fellowship.

Johann Hitzler, MD
Division of Hematology Oncology
The Hospital for Sick Children, Toronto, ON
Associate Professor, Department of Pediatrics, University of Toronto
Senior Scientist, Program Developmental and Stem Cell Biology; The Hospital for Sick Children Research Institute, Toronto, ON

Dr. Hitzler’s clinical and research interests focus on the leukemias of children with Down syndrome.
His experimental research uses mutational screens and xenograft model to determine the events that underlie the development of transient leukemia in newborns with Down syndrome and the progression to acute myeloid leukemia (AML). His clinical research focuses on how to improve treatment protocols for primary and relapsed acute lymphoblastic leukemia (ALL) in children with Down syndrome, specifically how to decrease the risk of severe infections during chemotherapy. He is involved
in the analysis of the infections experienced by children with Down syndrome while treated on current clinical trials for ALL conducted by the Children’s Oncology Group, the optimization of supportive care and the development of new treatment strategies for ALL in children with Down syndrome.

Krista Johnston, BScPT, MSocPT(c)
Physiotherapist
Haematology/Oncology/BMT
The Hospital for Sick Children, Toronto, ON

Krista Johnston is a full-time physiotherapist in the areas of haematology/oncology and bone marrow transplant. She provides in-patient assessment and treatment as well as out-patient consultation and has been part of the Neuroscience team at SickKids since 2007.

Krista has a status appointment with the University of Toronto and has active involvement in lecturing for the physiotherapy curriculum and is a preceptor for students. Krista has been a part of many hospital initiatives involving safe sleep and falls prevention in addition to initiatives to promote mobility and neurodevelopment. Krista has been involved in research with the brain tumor population and multi-centre research projects involving children with leukemia. She has just completed her own research looking at how children with cancer are mobilizing when admitted to hospital.

Nina Kadan-Lottick, MD, MSPH
Associate Professor of Pediatrics
Director of HEROS Survivorship Program
Leader Clinical Trial Program
Section of Pediatric Hematology-Oncology
Yale University School of Medicine, New Haven, CT

Dr. Kadan-Lottick, a pediatric hematologist-oncologist, is an Associate Professor at the Yale University School of Medicine and Director of the Yale HEROS Program for childhood cancer survivors. Dr. Kadan-Lottick’s research has concentrated on measuring and optimizing outcomes after treatment of childhood cancer, with an emphasis on leukemia. These studies have included cross-sectional and longitudinal studies of chemotherapy-induced cognitive changes, anxiety and depression, and family functioning during and after therapy. She was the principal investigator of two large multi-site longitudinal studies of quality of life outcomes and emotional functioning in children with acute lymphoblastic leukemia enrolled on front-line Children’s Oncology Group clinical trials. As a part of her focus on survivorship outcomes, Dr. Kadan-Lottick serves on the Children’s Oncology Group Survivorship Steering Committee, the Psychology Committee of the Childhood Cancer Survivorship Cohort Study, Consortium for New England Childhood Cancer Survivors Steering Committee, and the Board of Trustees for the Connecticut Chapter of the Leukemia and Lymphoma Society. She has also helped to author and revise the COG Long-Term Follow-up Guidelines.

E. Anders Kolb, MD
Associate Professor
Vice Chairman for Research
Department of Pediatrics
Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA
Director, Nemours Center for Cancer and Blood Disorders
Nemours/Alfred I. duPont Hospital for Children, Wilmington, DE

The laboratory and clinical work theme of E. Anders Kolb has been efficient and effective translation of novel therapies into children. A founding member of the National Cancer Institute funded Pediatric Preclinical Testing Program; Dr. Kolb is an end-user of banked, well-annotated clinical specimens and recognizes their inherent critical value to translational medicine. He has successfully completed preclinical evaluations of numerous anti-cancer strategies in human tissues and aided in the translation of these agents into clinical trials. Exploring the mechanism of action of targeted compounds, Dr. Kolb developed an expertise in genomics, proteomics and cell signaling to support diverse results-driven research and laboratory methodologies. Within the Children’s Oncology Group, Dr. Kolb serves as Chair, Myeloid Disease Committee; Member, Scientific Council; Member, Young Investigator Mentoring Committee and Member, Bone Tumor Committee. Through this, he has expertise and experience in collaborative science, resource stewardship, clinical research development, clinical trial design and implementation, and in the necessities of young investigator development. He has helped to design, implement and ensure adequate accrual onto pediatric treatment and banking studies. Progress and survival in pediatric diseases has reached a plateau. The ability of individual labs and programs to impact major improvements in care is diminishing. Progress through collaborative science is the clear path forward.

Wendy Landier, PhD, CRNP
Associate Professor, Pediatric Hematology/Oncology
Institute for Cancer Outcomes and Survivorship
University of Alabama at Birmingham, Birmingham, AL

Wendy Landier is a Pediatric Nurse Practitioner who has worked in pediatric oncology for over 30 years. She holds a Master’s degree in Nursing from UCLA and a PhD from the University of Hawaii. She is currently an Associate Professor in the Division of Pediatric Hematology/Oncology, Institute for Cancer Outcomes and Survivorship, in the School of Medicine, and also holds a secondary appointment in the School of Nursing, at the University of Alabama at Birmingham. Her career has primarily focused on childhood leukemia, lymphoma, and cancer survivorship, and her research focuses on understanding and improving health outcomes in children with leukemia and in cancer survivors. She current serves as Chair of the Children’s Oncology Group.
Nursing Discipline and as co-Chair of the COG Long-Term Follow-Up Guidelines Core Committee. She has published extensively regarding adherence to therapy in childhood leukemia, late effects in childhood cancer survivors, and the provision of patient/family education for parents of newly diagnosed pediatric oncology patients. She is co-PI of the Children’s Oncology Group study, “A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL”.

**Ellen M. Lavoie Smith, PhD, APRN, AOCN, FAAN**

*Associate Professor, Director PhD Program
University of Michigan School of Nursing, Ann Arbor, MI*

Ellen Lavoie Smith is an Associate Professor and PhD Program Director at the University of Michigan School of Nursing. Dr. Smith’s program of research is focused on finding new ways to predict, assess, and treat chemotherapy-induced peripheral neuropathy (CIPN) and associated neuropathic pain. She has received independent research funding from the National Institutes of Health, the Oncology Nursing Society, the American Cancer Society, Genentech, and Lilly Pharmaceuticals. She is the principal or co-investigator for five studies that will advance scientific knowledge related to CIPN. These studies include a NIH/NCI-funded R03 study designed to test and refine a patient-reported CIPN outcome measure, and an industry-sponsored (Genentech) study that is designed to test whether the Carevive® web-based care planning platform can be used to improve patient engagement in CIPN and pain assessment and self-management. Past research activities focused on evaluating the psychometric properties of several CIPN and pain measurement approaches for use in adults and children. Her most significant research role to date was as the principal investigator for a NIH/NCI-funded, multi-site cooperative group randomized placebo-controlled trial of duloxetine for painful CIPN, the results of which were reported in JAMA (2013).

**Jeff Lipton, PhD, MD, FRCPG**

*Professor of Medicine, University of Toronto
Staff Physician, Leukemia and Allogeneic Stem Cell Transplant Services
Princess Margaret Cancer Centre, Toronto, ON*

Dr. Lipton is Professor of Medicine at the University of Toronto and Staff Physician at Princess Margaret Cancer Centre (PMCC). He received an honors BSc in Biochemistry at the University of Calgary and a PhD in Biochemistry at Western University. An MRC post-doctoral fellowship at the Weizmann Institute in Israel with Leo Sachs led to his developing interests in leukemia. After a short time at the University of Connecticut, he had a mid-life crisis and went back to Calgary to go to medical school, followed by a residency in Internal Medicine. He then completed sub-specialty training in Medical Oncology at the University of Toronto and stayed on at the PMCC as a staff physician. His clinical practice is in chronic leukemias and bone marrow failure syndromes as well as allogeneic stem cell transplant. Research interests in particular are in CML and its therapy, outcomes and supportive care in BMT, and in the therapy of bone marrow failure syndromes. Dr. Lipton served as President of the Canadian Bone Marrow Transplant Group and is on the advisory boards relating to the therapy of CML including the International CML Foundations and the European Leukemia Net (ELN). He has authored or co-authored more than 320 peer reviewed papers and 400 abstracts.

**Mignon Loh, MD**

*Benioff UCSF Professorship in Children’s Health
Deborah and Arthur Ablin Endowed Chair in Pediatric Molecular Oncology
Division Chief, Hematology Oncology
University of California Benioff Children’s Hospital, San Francisco, CA*

Dr. Loh studies two childhood blood cancers, Acute Lymphoblastic Leukemia (ALL) and Juvenile Myelomonocytic Leukemia (JMML). She is nationally and internationally recognized for her expertise and novel contributions in these disorders. Her lab has made seminal contributions to unraveling the genetics of JMML. She currently serves as the Chair of the ALL committee of the Children’s Oncology Group (COG), and works with a group of dedicated investigators to open clinical trials for affected children with both newly diagnosed and relapsed disease. The large number of banked samples acquired from these patients has provided additional rich resources for the ALL group to identify additional abnormalities that are providing new insights into the causes of this most common cancer of childhood. Most recently, the identification of kinase activating lesions in up to 15% of patients with high risk ALL has led to two major clinical trials that employ “precision medicine” approaches to augment traditional chemotherapy.

**David Malkin, MD, FRCPG**

*Professor of Pediatrics and Medical Biophysics, University of Toronto
Staff Oncologist, Division of Hematology/Oncology
Senior Scientist, Genetics & Genomic Biology Program, Research Institute
The Hospital for Sick Children, Toronto, ON*

Dr. Malkin is Professor of Pediatrics and Medical Biophysics, POGO Chair in Cancer Control, Faculty of Medicine, University of Toronto, and Medical Director of the Pediatric Oncology Group of Ontario. He is a pediatric oncologist, Director of the Cancer Genetics program, and a Senior Scientist in the Genetics and Genome Biology Program at SickKids. He is co-Director of the SickKids Cancer Sequencing (KiCS) program which integrates and translates next generation sequencing into clinical care of children with cancer,
Mark Minden, PhD, MD, FRCPC  
Staff Physician/Senior Scientist  
Princess Margaret Cancer Centre, Toronto, ON  
Orsino Chair in Leukemia Research  
Professor, University of Toronto

Dr. Minden grew up in Hamilton where he was introduced to hematology at the Zipursky house. He graduated from U of T medical school in 1974. Following residency in Toronto he undertook a PhD with Drs. Till and McCulloch in cell biology/leukemia research. Subsequently Dr. Minden moved to Boston where he was a clinical oncology fellow under Tom Frei at the Sidney Farber Cancer Center and a basic research fellow with David Housman at MIT. In 1982 he returned to the Princess Margaret Hospital/Ontario Cancer Institute as a clinician scientist.

Dr. Minden’s laboratory research has focused on genetic changes in AML and ALL cells, and the identification of novel agents to kill leukemic cells. Dr. Minden is director of the leukemia live cell tissue bank that provides cells to researchers throughout Toronto and around the world.

In the clinic Dr. Minden is involved in the treatment of AML and ALL in young and older adults. With Dr. Joe Brandwein, he adapted the successful pediatric DFCI ALL protocol for use in patients age 18 and older; this is now the standard of care at the Princess Margaret. Dr. Minden works with the AYA program to follow patients post-SickKids treatment.

Steven D. Mittelman, MD, PhD  
Director, Diabetes & Obesity Program  
Center for Endocrinology, Diabetes & Metabolism  
Associate Professor, Departments of Pediatrics and Physiology & Biophysics  
MD/PhD Program Director, Keck School of Medicine, University of Southern California, Los Angeles, CA

Dr. Steven Mittelman received his MD/PhD from the Keck School of Medicine, where he investigated the physiology of glucose regulation in obesity and diabetes. He completed his residency in pediatrics and fellowship in pediatric endocrinology at Children’s Hospital Los Angeles. Dr. Mittelman’s research focuses on the relationships between obesity and acute lymphoblastic leukemia. His lab investigates the various mechanisms whereby fat tissue protects leukemia cells and makes them better able to resist chemotherapy. In addition, Dr. Mittelman is studying how body weight and other nutritional factors like vitamin D might impact patients with leukemia both before and after treatment. His bench and clinical research have led to a clinical intervention aimed at assessing whether healthy diet and activity during leukemia treatment could improve outcome in children.

When not in the lab, Dr. Mittelman sees patients in the CHLA EMPOWER Weight Management Clinic, which he helped launch. In addition, Dr. Mittelman founded The CHLA Diabetes and Obesity Program in response to the huge burden that childhood obesity places on our patients and our community. Dr. Mittelman is the Director of the Keck School of Medicine/Caltech Combined MD/PhD Program, and the Founding Director of the CHLA Donnell Society for Pediatric Scientists.

Paul Nathan, MD, MSc, FRCPC  
Director, AfterCare Program  
Division of Hematology/Oncology  
The Hospital for Sick Children, Toronto

Dr. Nathan is Director of the AfterCare clinic in the Division of Pediatric Hematology/ Oncology at the Hospital for Sick Children (SickKids). He is a Senior Associate Scientist in the SickKids Research Institute and an Associate Professor of Pediatrics and Health Policy, Management and Evaluation at the University of Toronto. His research is focused on long-term outcomes in survivors of childhood cancer. He studies specific “late effects” of cancer therapy, including cardiac disease and second malignant neoplasms. Much of his research focuses on health care utilization and its relationship with long-term outcomes in adult survivors of childhood cancer. He is a member of several North American research and clinical committees focused on research, clinical care, and policy creation for long-term survivors of childhood cancer, including the Children’s Oncology Group Survivorship and Outcomes Committee, and the Childhood Cancer Survivor Study (CCSS).

Ching-Hon Pui, MD  
Chair, Department of Oncology  
St. Jude Children’s Research Hospital, Memphis, TN

Dr. Ching-Hon Pui is chair of the Oncology Department and the Fahad Nassar Al-Rashid Chair of Leukemia
Research at St. Jude Children’s Research Hospital and an American Cancer Society Clinical Research Professor. His research contributes to improved cure rate of childhood acute lymphoblastic leukemia (ALL) toward 90%, while concomitantly improve the quality of life of survivors by successfully eliminating irradiation in all patients. He has cofounded an International childhood ALL research consortium, organized annual teaching conference in Asia, influenced the development of a new Chinese Medical Insurance Policy starting with childhood ALL, and established the first China National Childhood ALL Study Group. Dr Pui has authored over 750 peer-reviewed original articles and more than 150 book chapters and reviews. He has edited nine books and monographs on leukemia, and serves as section editor or on editorial boards of many journals. He is an elected member of the American Society for Clinical Investigation, the Association of American Physicians, Academia Sinica Taiwan, and Chinese Academy of Engineering, and is also a fellow of the American Association for the Advancement of Science.

Stephen Sallan, MD
Chief of Staff, Emeritus
Dana Farber Cancer Institute, Boston, MA

Dr. Stephen E. Sallan is Chief of Staff, Emeritus and the Quick Family Senior Investigator in Pediatric Oncology at Dana-Farber Cancer Institute, and a Professor of Pediatrics at Harvard Medical School.

Dr. Sallan is one of the world’s foremost experts on childhood leukemia. His principal contributions include optimizing the use of asparaginase in acute lymphoblastic leukemia (ALL), enhancing outcomes in young adults with ALL, developing “therapeutic windows” for newly diagnosed patients, preventing therapy-related cardiotoxicity, and exploring innovative approaches to the prevention of chemotherapy-induced nausea and vomiting.

After completing his education at Wayne State University in Detroit, he trained in pediatrics at Boston Floating Hospital, Children's Hospital of Philadelphia, and the Hospital for Sick Children, Great Ormond Street, London.

Since 1972, he has pursued his clinical and research career at Boston Children's Hospital and the Dana Farber Cancer Institute.

Marina Salvadori, MD, FRCP(C)
Professor of Paediatrics
University of Western Ontario, London, ON
Paediatric Infectious Diseases Consultant
Children’s Hospital of Western Ontario, London, ON

Marina Salvadori graduated from medicine at Queen’s University in 1991.

She did her residency training in pediatrics at the University of Manitoba, Winnipeg, then trained in Infectious Diseases at The Hospital For Sick Children in Toronto. She was working there in May 2000, and joined a team of pediatricians who responded to the call for help from Walkerton. She spent the summer of 2000 working in Walkerton, then moved to London in October 2000. She is currently an infectious diseases consultant at the Children’s Hospital, London Health Sciences Center and a Professor at the Schulich School of Medicine and Dentistry at the University of Western Ontario. She is the recipient of numerous teaching awards. She is very interested in vaccine preventable diseases, immunization education and advocacy. Dr Salvadori is a member of the National Advisory Committee on Immunization, a Past member of the Canadian Immunization and Infectious Diseases Committee.

Lillian Sung, MD, PhD
Professor, The University of Toronto
The Hospital for Sick Children, Toronto, ON

Dr. Lilian Sung is a Full Professor and Senior Scientist at The Hospital for Sick Children, Toronto, Ontario, Canada. She is certified in the specialties of pediatrics, infectious diseases, hematology and clinical investigation. She completed a PhD in Clinical Epidemiology from the University of Toronto in 2004. She has a clinical research program focused on supportive care for children with cancer. Her methodological focus is on randomized and observational trials, meta-analysis, and patient-reported outcomes. She is the principal investigator on multiple operating grants from the National Institutes of Health (NIH), Canadian Cancer Society Research Institute and the Canadian Institutes of Health Research.

Dr. Sung is the Chair of Cancer Control and Supportive Care in the Children’s Oncology Group (COG). COG is the largest pediatric cancer clinical trials consortium and includes over 200 member institutions. She is the co-PI on the NCI Community Oncology Research Program (NCORP) Research Base grant which supports the Cancer Control and Supportive Care program within COG. Dr. Sung is also the co-PI on an NIH R25 grant to support the Clinical Research Training Institute, sponsored by the American Society of Hematology.

Jeffrey Taub, MD
Division Chief of Oncology
Children’s Hospital of Michigan, Detroit, MI
Professor of Pediatrics
Ring Screw Textron Chair in Pediatric Cancer Research
Wayne State University School of Medicine, Detroit, MI

Dr. Taub received his medical degree from the University of Western Ontario, completed his internship at Victoria Hospital in London, Ontario, and a Pediatric Residency and Pediatric Hematology/Oncology
Fellowship at Children’s Hospital of Michigan. Dr. Taub is currently the Division Chief of Oncology at Children’s Hospital of Michigan and is a Professor of Pediatrics at Wayne State University School of Medicine where he holds the Ring Screw Textron Endowed Chair in Pediatric Cancer Research. He has been the past recipient of several research awards including a Young Investigator Award from the American Society of Clinical Oncology, a Wayne State University Faculty Research Excellence Award and a Children’s Hospital of Michigan Teacher of the Year Award. He clinical expertise is in the field of leukemia with a particular focus on children with Down syndrome and leukemia. He has conducted multiple research projects related to the epidemiology and pharmacology of childhood leukemia and has published over 100 research papers, abstracts and book chapters.

Leanne Ward, MD, FRCPC, FAAP
Research Chair in Pediatric Bone Health
Associate Professor of Pediatrics
University of Ottawa
Pediatric Endocrinologist
Division of Endocrinology and Metabolism
Children’s Hospital of Eastern Ontario, Ottawa, ON

Dr. Leanne Ward is an Associate Professor of Pediatrics at the University of Ottawa where she has held a Research Chair in Pediatric Bone Health since 2010. She is the Medical Director of the Pediatric Bone Health Clinical and Research Programs at the Children’s Hospital of Eastern Ontario and a pediatric endocrinologist within the Division of Endocrinology and Metabolism. Dr. Ward’s research program is dedicated to the study of bone development and the treatment of bone disorders in children. She has been the principal investigator of the “STOPP” research program (STeroid-induced Osteoporosis in the Pediatric Population), a pan-Canadian project funded by the Canadian Institutes of Health Research to evaluate the effect of glucocorticoids on bone health in children with serious illnesses. She has served as an endocrinology and bone health advisor to numerous national and international organizations on various aspects of skeletal health in children, including the Centres for Disease Control Clinical Care Guidelines for Duchenne Muscular Dystrophy. Dr. Ward has received a number of awards for her work in pediatric bone health, including a Canadian Child Health Clinician Scientist Career Development Award, a Canadian Institutes for Health Research New Investigator Award, a Canadian Child Health Clinician Scientist Career Enhancement Award, and two, five-year Research Chairs in Pediatric Bone Health (University of Ottawa, 2010 and 2015).

Jim Whitlock, MD
Division Head and Women’s Auxiliary Millennium Chair
Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON
Senior Associate Scientist, Child Health Evaluative Sciences Program, SickKids Research Institute
Professor of Paediatrics, University of Toronto

Dr. James A. Whitlock is the Division Head and Women’s Auxiliary Millennium Chair in Haematology/Oncology at The Hospital for Sick Children, Senior Associate Scientist in the Child Health Evaluative Sciences Program at SickKids Research Institute, and Professor of Paediatrics at the University of Toronto. Dr. Whitlock’s research interests include the biology and treatment of childhood acute leukemias, the development of new drugs for the treatment of childhood cancers, and the biology and treatment of histiocytic disorders. He is the past Vice-Chair for New Agents and Relapse studies for the Acute Lymphoblastic Leukemia Committee of the Children’s Oncology Group, and has been Chair or Vice-Chair of several COG clinical trials. He is the elected chair of the Steering & Prioritization Committee of the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) consortium, and the immediate Past President of the Histiocyte Society, an international scientific organization which supports research in, and conducts clinical trials for, histiocytic disorders. In these roles, he has been involved in the pediatric development of numerous novel agents, including blinatumomab, inotuzumab and CTL019 anti-CD19 CAR T-cells.

Sue Zupanec, MN, NP Pediatrics
Nurse Practitioner, Leukemia and Lymphoma Program
The Hospital for Sick Children, Toronto, ON

Sue completed her Master’s of Nursing with Pediatric Nurse Practitioner Certificate in April 2003. Since completing her Masters, Sue has worked as a Nurse Practitioner within the Leukemia/Lymphoma section at the Hospital for Sick Children. In the Fall of 2015, Sue joined the Children’s Oncology Group Nursing Steering Committee and holds the position of COG Nursing Education Chair. Sue is also one of the assigned nurses within the core COG nursing group for Acute Lymphoblastic Leukemia (ALL) and serves as the study nurse for the current Phase 3 trial AALL1331. AALL1331 aims to study if the addition of Blinatumomab will improve event free survival for patients who have a first relapse of B lineage ALL.
POGO wishes to thank the Ontario Ministry of Health & Long-Term Care and these sponsors for their generous support of the 2016 POGO Multi-Disciplinary Symposium on Childhood Cancer.